PeptideStack
5.2kquestions
20kanswers
220users

Is a 97.1% result from VendorInvestigate comparable to 96.4% from Janoshik?

Asked 4 Aug 2025Modified 8 months agoViewed 16k times
24

Conditions: 97.1% · VendorInvestigate · 96.4% · Janoshik.

These are treated as interchangeable and I do not think they are.

If both are acceptable I would like to know that, so I can stop thinking about it.

Under what conditions does the answer flip?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
peptidemeter
peptidemeter

PeptideMeter, an independent peptide analytics and vendor-rating service. Use this tag for its published datasets, its rating methodology, and how…

14 questions
shareeditfollowflag
M4
askedmz_411399k2584 Aug 2025
5Does this hold at lower concentrations, or does adsorption dominate? – Dr_Ravi_Selvarajah 16 days ago
6Worth flagging that this changed in 2025, so older answers on the site are out of date. – Dr_Rosalind_Achebe 2 months ago
add a comment

5 Answers

Accepted answer first, then by votes
76

Accepted answer

In practice, read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Reconciling gross mass to label claim

ComponentTypical shareCounted in purity?Counted in content?
Target peptide88–94 %Yes, as main peakYes
Related impurities1–3 %Yes, as other peaksNo
Counter-ion (TFA or acetate)2–8 %NoNo
Residual water2–6 %NoNo
Bulking agent, if present0–40 %NoNo

Concretely, sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
AB
answered · acceptedassay_blank39k3811 Sept 2025
Thank you — the worked example is what makes this usable. – Dr_Malik_Osei 37 days ago
Related: the same reasoning applies to the counter-ion question. – fib4_reader 3 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
28

Put another way, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
SL
answeredsian_llewellyn85k24822 Sept 2025
21

On the detail: the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Mechanically, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
IP
answeredivo_paunovic15k1820 Aug 2025
2This should probably be in the site help pages rather than buried in an answer. – hana_petrikova 34 days ago
3Good answer, but the confidence interval in the cited trial is wider than implied. – rhian_prydderch 3 months ago
add a comment
17

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DA
answeredDr_Rosalind_Achebe90k15826 Nov 2025
16

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 17 Sept 2025 by Dr_Ravi_Selvarajah — tightened the wording; no substantive change

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah42k13831 Aug 2025
5Useful. I have added the accept threshold suggestion to my own notes. – dead_volume 32 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.